<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Orthop Traumatol</journal-id><journal-id journal-id-type="iso-abbrev">J Orthop Traumatol</journal-id><journal-title-group><journal-title>Journal of Orthopaedics and Traumatology : Official Journal of the Italian Society of Orthopaedics and Traumatology</journal-title></journal-title-group><issn pub-type="ppub">1590-9921</issn><issn pub-type="epub">1590-9999</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26577936</article-id><article-id pub-id-type="pmc">4805636</article-id><article-id pub-id-type="publisher-id">388</article-id><article-id pub-id-type="doi">10.1007/s10195-015-0388-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effectiveness of intra-articular injections of sodium hyaluronate-chondroitin sulfate in knee osteoarthritis: a multicenter prospective study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Rivera</surname><given-names>Fabrizio</given-names></name><address><phone>+39-3472992578</phone><email>rivgio@libero.it</email></address><xref ref-type="aff" rid="Aff1"></xref><xref ref-type="aff" rid="Aff9"></xref></contrib><contrib contrib-type="author"><name><surname>Bertignone</surname><given-names>Luca</given-names></name><xref ref-type="aff" rid="Aff2"></xref><xref ref-type="aff" rid="Aff3"></xref></contrib><contrib contrib-type="author"><name><surname>Grandi</surname><given-names>Giancarlo</given-names></name><xref ref-type="aff" rid="Aff4"></xref></contrib><contrib contrib-type="author"><name><surname>Camisassa</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="Aff4"></xref></contrib><contrib contrib-type="author"><name><surname>Comaschi</surname><given-names>Guido</given-names></name><xref ref-type="aff" rid="Aff5"></xref></contrib><contrib contrib-type="author"><name><surname>Trentini</surname><given-names>Diego</given-names></name><xref ref-type="aff" rid="Aff6"></xref></contrib><contrib contrib-type="author"><name><surname>Zanone</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="Aff7"></xref></contrib><contrib contrib-type="author"><name><surname>Teppex</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="Aff7"></xref></contrib><contrib contrib-type="author"><name><surname>Vasario</surname><given-names>Gabriele</given-names></name><xref ref-type="aff" rid="Aff7"></xref></contrib><contrib contrib-type="author"><name><surname>Fortina</surname><given-names>Giorgio</given-names></name><xref ref-type="aff" rid="Aff8"></xref></contrib><aff id="Aff1"><label></label>Department of Orthopedic Trauma, SS Annunziata Hospital, Savigliano, CN Italy </aff><aff id="Aff2"><label></label>Sant’Anna Clinic, Casale Monferrato, AL Italy </aff><aff id="Aff3"><label></label>Eporediese Hospital, Ivrea, TO Italy </aff><aff id="Aff4"><label></label>La Vialarda Clinic, Biella, Italy </aff><aff id="Aff5"><label></label>Sestri Ponente Hospital, Genova, Italy </aff><aff id="Aff6"><label></label>Department of Orthopedics and Traumatology, IRCCS A.O.U. San Martino-IST, Genova, Italy </aff><aff id="Aff7"><label></label>Department of Orthopedics and Traumatology, AO CTO Hospital, Turin, Italy </aff><aff id="Aff8"><label></label>Santa Rita Clinic, Vercelli, Italy </aff><aff id="Aff9"><label></label>Via Servais 200 A 16, Turin, Italy </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2016</year></pub-date><volume>17</volume><issue>1</issue><fpage>27</fpage><lpage>33</lpage><history><date date-type="received"><day>16</day><month>9</month><year>2015</year></date><date date-type="accepted"><day>28</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>© The Author(s) 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="4981" xml_f="4991" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="5002" xml_f="5208" txt_i="22" txt_f="228">Intra-articular injection of hyaluronic acid is a well-established therapy for the treatment of knee osteoarthritis. The aim of the study was to assess the effectiveness and safety of the use of Arthrum HCS</offsets><sup><offsets xml_i="5213" xml_f="5214" txt_i="228" txt_f="229">®</offsets></sup><offsets xml_i="5220" xml_f="5283" txt_i="229" txt_f="292"> (40 mg hyaluronic acid and 40 mg chondroitin sulfate in 2 mL).</offsets></p></sec><sec><title><offsets xml_i="5305" xml_f="5326" txt_i="294" txt_f="315">Materials and methods</offsets></title><p><offsets xml_i="5337" xml_f="5716" txt_i="316" txt_f="695">This was an open, multicenter, prospective study. Men or women over 40 years of age with documented knee osteoarthritis and WOMAC subscore A (severity of pain) ≥25 were enrolled. They received three weekly intra-articular injections of sodium hyaluronate 2 % and chondroitin sulfate 2 % in combination. WOMAC subscore A was assessed at 1, 3 and 6 months after the last injection.</offsets></p></sec><sec><title><offsets xml_i="5738" xml_f="5745" txt_i="697" txt_f="704">Results</offsets></title><p><offsets xml_i="5756" xml_f="5915" txt_i="705" txt_f="864">One hundred and twelve patients were included (women, 66 %). The mean (SD) WOMAC subscore A decreased from 52.1 (15.2) at inclusion to 20.5 (19.7) at month 6 (</offsets><italic><offsets xml_i="5923" xml_f="5924" txt_i="864" txt_f="865">P</offsets></italic><offsets xml_i="5933" xml_f="6044" txt_i="865" txt_f="973"> &lt; 0.0001). The mean subscore was already significantly decreased 1 month after the last injection at 25.7 (</offsets><italic><offsets xml_i="6052" xml_f="6053" txt_i="973" txt_f="974">P</offsets></italic><offsets xml_i="6062" xml_f="6501" txt_i="974" txt_f="1410"> &lt; 0.0001). Pain relief and consumption of analgesic drugs, both assessed with visual analogic scale (VAS), consistently decreased. The investigators were satisfied/very satisfied as regards the therapeutic effectiveness of sodium hyaluronate-chondroitin sulfate in reducing pain (77 %), improving mobility (78 %) and reducing the consumption of analgesics (74 %). Only one adverse effect was reported by one patient (knee tumefaction).</offsets></p></sec><sec><title><offsets xml_i="6523" xml_f="6533" txt_i="1412" txt_f="1422">Conclusion</offsets></title><p><offsets xml_i="6544" xml_f="6612" txt_i="1423" txt_f="1491">These results suggest that intra-articular injections of Arthrum HCS</offsets><sup><offsets xml_i="6617" xml_f="6618" txt_i="1491" txt_f="1492">®</offsets></sup><offsets xml_i="6624" xml_f="6799" txt_i="1492" txt_f="1667"> (sodium hyaluronate plus chondroitin sulfate) in patients with knee osteoarthritis are efficient and safe. These results should be confirmed in a randomized controlled study.</offsets></p></sec><sec><title><offsets xml_i="6821" xml_f="6838" txt_i="1669" txt_f="1686">Level of evidence</offsets></title><p><offsets xml_i="6849" xml_f="6852" txt_i="1687" txt_f="1690">IV.</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Knee osteoarthritis</kwd><kwd>Intra-articular injection</kwd><kwd>Sodium hyaluronate</kwd><kwd>Chondroitin sulfate</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title><offsets xml_i="7292" xml_f="7304" txt_i="1699" txt_f="1711">Introduction</offsets></title><p><offsets xml_i="7315" xml_f="7412" txt_i="1712" txt_f="1809">It is estimated that around 250 million people in the world are affected by knee osteoarthritis [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="7444" xml_f="7445" txt_i="1809" txt_f="1810">1</offsets></xref><offsets xml_i="7452" xml_f="7774" txt_i="1810" txt_f="2132">]. Knee pain has an important impact by limiting activity and impairing quality of life. Thus, knee osteoarthritis has been identified as one of the medical conditions (with stroke, depression, hip fracture and heart disease) accounting for more physical disability than other diseases in people 65 years of age or older [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="7806" xml_f="7807" txt_i="2132" txt_f="2133">2</offsets></xref><offsets xml_i="7814" xml_f="7887" txt_i="2133" txt_f="2206">]. Moreover, knee osteoarthritis has a major impact on healthcare costs [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="7919" xml_f="7920" txt_i="2206" txt_f="2207">3</offsets></xref><offsets xml_i="7927" xml_f="7928" txt_i="2207" txt_f="2208">–</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="7960" xml_f="7961" txt_i="2208" txt_f="2209">6</offsets></xref><offsets xml_i="7968" xml_f="7970" txt_i="2209" txt_f="2211">].</offsets></p><p><offsets xml_i="7977" xml_f="8341" txt_i="2212" txt_f="2576">The management of osteoarthritis should be hierarchical, with non pharmacological methods as first interventions (weight loss, exercise and braces), followed by analgesic drugs [nonsteroidal anti-inflammatory drugs (NSAIDs) and other analgesics], local therapies (topical NSAIDs, intra-articular corticosteroids and hyaluronic acid), and surgery as a last resort [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="8373" xml_f="8374" txt_i="2576" txt_f="2577">7</offsets></xref><offsets xml_i="8381" xml_f="8382" txt_i="2577" txt_f="2578">–</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="8415" xml_f="8417" txt_i="2578" txt_f="2580">10</offsets></xref><offsets xml_i="8424" xml_f="8426" txt_i="2580" txt_f="2582">].</offsets></p><p><offsets xml_i="8433" xml_f="8974" txt_i="2583" txt_f="3124">Administration of exogenous hyaluronic acid (viscosupplementation) directly into the joint is available as a treatment for the symptoms of knee osteoarthritis. The purpose of viscosupplementation is to overcome the qualitative and quantitative deficiency of hyaluronic acid that is associated with osteoarthritis. Hyaluronic acid is a polysaccharide that is the main constituent of cartilage and synovial fluid; it is responsible for the mechanical properties of the joint by allowing shock absorption, lubrication and cartilage protection [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="9007" xml_f="9009" txt_i="3124" txt_f="3126">11</offsets></xref><offsets xml_i="9016" xml_f="9165" txt_i="3126" txt_f="3275">]. In osteoarthritis patients, synovial hyaluronate is depolymerized and is cleared at higher rates compared to normal subjects due to inflammation [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="9198" xml_f="9200" txt_i="3275" txt_f="3277">12</offsets></xref><offsets xml_i="9207" xml_f="9337" txt_i="3277" txt_f="3407">]. Intra-articular injections of hyaluronic acid have been shown to be as effective as NSAIDs with fewer systemic adverse events [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="9370" xml_f="9372" txt_i="3407" txt_f="3409">13</offsets></xref><offsets xml_i="9379" xml_f="9507" txt_i="3409" txt_f="3537">]; this therapy has a delayed onset of action in comparison with intra-articular corticosteroids, but a longer-lasting benefit [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="9540" xml_f="9542" txt_i="3537" txt_f="3539">14</offsets></xref><offsets xml_i="9549" xml_f="9671" txt_i="3539" txt_f="3661">]. Younger patients and patients at an earlier stage of the disease are more likely to benefit from viscosupplementation [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="9704" xml_f="9706" txt_i="3661" txt_f="3663">15</offsets></xref><offsets xml_i="9713" xml_f="9715" txt_i="3663" txt_f="3665">].</offsets></p><p><offsets xml_i="9722" xml_f="9733" txt_i="3666" txt_f="3677">Arthrum HCS</offsets><sup><offsets xml_i="9738" xml_f="9739" txt_i="3677" txt_f="3678">®</offsets></sup><offsets xml_i="9745" xml_f="10007" txt_i="3678" txt_f="3940"> (LCA Pharmaceutical, Chartres, France) is a new specialty for viscosupplementation combining sodium hyaluronate and chondroitin sulfate. Chondroitin sulfate—a sulfated glycosaminoglycan—is an important structural component of the extracellular cartilage matrix.</offsets></p><p><offsets xml_i="10014" xml_f="10598" txt_i="3941" txt_f="4525">On the articular system, chondroitin sulfate links to monomers with high molecular weights. The proteoglycan aggregate exhibits viscoelastic and hydration properties and an ability to interact with the surrounding tissue through electric charges, leading to protection of the cartilaginous tissues. Furthermore, chondroitin sulfates are inhibitors of extracellular proteases involved in the metabolism of connective tissues and stimulate proteoglycan production by chondrocytes in vitro; they also inhibit cartilage cytokine production and induce apoptosis of articular chondrocytes [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="10631" xml_f="10633" txt_i="4525" txt_f="4527">16</offsets></xref><offsets xml_i="10640" xml_f="10992" txt_i="4527" txt_f="4879">]. Preliminary clinical trials were in favor of the effectiveness of intra-articular injections of sodium hyaluronate-chondroitin sulfate. Thus, in a 3-month multicentric pilot study, a series of three weekly injections of a combination of hyaluronic acid-chondroitin sulfate was well tolerated and decreased pain in patients with knee osteoarthritis [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="11025" xml_f="11027" txt_i="4879" txt_f="4881">17</offsets></xref><offsets xml_i="11034" xml_f="11270" txt_i="4881" txt_f="5117">]. A recent clinical study suggested that a single injection of sodium hyaluronate-chondroitin sulfate in patients with lateral epicondylitis offer better pain benefits for 6 months after injection than intra-articular corticosteroids [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="11303" xml_f="11305" txt_i="5117" txt_f="5119">18</offsets></xref><offsets xml_i="11312" xml_f="11506" txt_i="5119" txt_f="5313">]. In an exploratory study, the effectiveness of intra-articular injections of a solution combining hyaluronic acid and chondroitin sulfate was assessed in 40 patients with knee osteoarthritis [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="11539" xml_f="11541" txt_i="5313" txt_f="5315">19</offsets></xref><offsets xml_i="11548" xml_f="11933" txt_i="5315" txt_f="5700">]. The clinical improvement, together with the changes of the ultrasound parameters and biomarkers of cartilage metabolism and joint inflammation, suggested a non-placebo effect. These results prompted us to assess in a prospective multicenter study the effectiveness and safety of the use of hyaluronic acid when combined with chondroitin sulfate in patients with knee osteoarthritis.</offsets></p></sec><sec id="Sec2" sec-type="materials|methods"><title><offsets xml_i="11994" xml_f="12015" txt_i="5702" txt_f="5723">Materials and methods</offsets></title><sec id="Sec3"><title><offsets xml_i="12045" xml_f="12057" txt_i="5724" txt_f="5736">Study design</offsets></title><p><offsets xml_i="12068" xml_f="12314" txt_i="5737" txt_f="5983">This was an open, multicenter, prospective study, assessing the effectiveness of three intra-articular injections of sodium hyaluronate plus chondroitin sulfate (40 mg of each compound in 2 mL) in the symptomatic treatment of knee osteoarthritis.</offsets></p><p><offsets xml_i="12321" xml_f="12486" txt_i="5984" txt_f="6149">The study was conducted prospectively by office or hospital specialists (orthopedic surgeons, rehabilitation medicine physicians) from October 2012 to December 2013.</offsets></p><p><offsets xml_i="12493" xml_f="12599" txt_i="6150" txt_f="6256">Written informed consent was obtained from each patient. The protocol was conducted in accordance with the</offsets><italic><offsets xml_i="12607" xml_f="12672" txt_i="6256" txt_f="6321"> Declaration of Helsinki and Guidelines on Good Clinical Practice</offsets></italic><offsets xml_i="12681" xml_f="12723" txt_i="6321" txt_f="6363"> and approved by a local ethics committee.</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="12755" xml_f="12773" txt_i="6365" txt_f="6383">Inclusion criteria</offsets></title><p><offsets xml_i="12784" xml_f="12986" txt_i="6384" txt_f="6586">Men or women over 40 years of age were eligible to participate if they: (1) had documented knee osteoarthritis evidenced with X-rays over the past 6 months with Kellgren-Lawrence score grade II or III [</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="13019" xml_f="13021" txt_i="6586" txt_f="6588">20</offsets></xref><offsets xml_i="13028" xml_f="13168" txt_i="6588" txt_f="6728">]; (2) had pain and functional impairment for at least 3 months and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="13201" xml_f="13203" txt_i="6728" txt_f="6730">21</offsets></xref><offsets xml_i="13210" xml_f="14632" txt_i="6730" txt_f="8152">] subscore A (severity of pain) ≥25 (on a scale of 100); and (3) needed hyaluronic acid injections after the failure or intolerance to first-line analgesics or non steroidal anti-inflammatory drugs. The main exclusion criteria were: severe hydrarthrosis; inflammatory rheumatism; history of knee trauma in the past 6 months; history of arthroplasty or major surgery on the target knee in the past 6 months; history of arthroscopy or surgery on the target knee in the past 3 months; planned knee surgery during the study; history of septic arthritis of the knee; knee wound or skin condition; crural or sciatic radiculalgia of the lower limb; tendinopathy; symptomatic homolateral or contralateral hip disease; venous or lymphatic stenosis of the lower limb; medical history of venous thromboembolism (including pulmonary embolism) or patient with high risk of venous thromboembolism; patient with a history of auto-immune disease; treatment with diacerein, avocado soy unsaponifiables, glucosamine sulfate/chondroitin starting less than 3 months previously or with dosage modified during the past 3 months; recurrent episodes of chondrocalcinosis; previous treatment with viscosupplementation; injection of corticosteroids into the knee under study less than 3 months previously; known hypersensitivity to hyaluronic acid or substances with similar activity; ongoing anticoagulant therapy; pregnant or breastfeeding women.</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="14664" xml_f="14698" txt_i="8154" txt_f="8188">Treatment and clinical assessments</offsets></title><p><offsets xml_i="14709" xml_f="14975" txt_i="8189" txt_f="8455">Demographic, description and history of knee osteoarthritis, concomitant treatments and WOMAC subscore A were recorded at inclusion visit. The WOMAC (Western Ontario and McMaster Universities) index is used to assess patients with osteoarthritis of the hip or knee [</offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="15008" xml_f="15010" txt_i="8455" txt_f="8457">21</offsets></xref><offsets xml_i="15017" xml_f="15331" txt_i="8457" txt_f="8771">]. The subscore A of the index is for pain assessment in five different circumstances: during walking (A1), using stairs (A2), in bed (A3), sitting or lying (A4) and standing (A5). For each item, pain is graded from 0 (none) to 100 (extreme). The sum for the five items is divided by five to give WOMAC subscore A.</offsets></p><p><offsets xml_i="15338" xml_f="15403" txt_i="8772" txt_f="8837">Patients received three intra-articular injections of Arthrum HCS</offsets><sup><offsets xml_i="15408" xml_f="15409" txt_i="8837" txt_f="8838">®</offsets></sup><offsets xml_i="15415" xml_f="15654" txt_i="8838" txt_f="9077"> (40 mg hyaluronic acid and 40 mg chondroitin sulfate in 2 mL) 1 week apart. Assessment of treatment effectiveness and safety was performed during follow-up visits at 1 month, 3 months and 6 months after the last intra-articular injection.</offsets></p><p><offsets xml_i="15661" xml_f="16027" txt_i="9078" txt_f="9444">The effectiveness assessment during the follow-up visits included: WOMAC subscore A, relief of pain using a visual analogic scale (VAS) ranging from 0 (“maximum relief”, i.e., no pain) to 100 (“no relief”, i.e., maximal pain) and consumption of analgesic drugs using a VAS ranging from 0 (“no consumption of analgesics”) to 100 (“maximal consumption of analgesics)”.</offsets></p><p><offsets xml_i="16034" xml_f="16128" txt_i="9445" txt_f="9539">Adverse events were recorded immediately after the injections and during the follow-up visits.</offsets></p></sec><sec id="Sec6"><title><offsets xml_i="16160" xml_f="16180" txt_i="9541" txt_f="9561">Statistical analysis</offsets></title><p><offsets xml_i="16191" xml_f="16257" txt_i="9562" txt_f="9628">Data from previous studies were used to estimate the sample size [</offsets><xref ref-type="bibr" rid="CR22"><offsets xml_i="16290" xml_f="16292" txt_i="9628" txt_f="9630">22</offsets></xref><offsets xml_i="16299" xml_f="16301" txt_i="9630" txt_f="9632">, </offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="16334" xml_f="16336" txt_i="9632" txt_f="9634">23</offsets></xref><offsets xml_i="16343" xml_f="16538" txt_i="9634" txt_f="9829">] With a loss to follow-up equal to 10 %, it was estimated that a sample size of 122 patients would provide 50 % power to detect a significant change of WOMAC subscore A (with alpha-risk at 5 %).</offsets></p><p><offsets xml_i="16545" xml_f="16988" txt_i="9830" txt_f="10273">The primary endpoint was the change of WOMAC subscore A from inclusion to end of study. The secondary endpoints were the change of WOMAC subscore A from inclusion to month 1 or month 3, relief of pain at months 1, 3 and 6, consumption of analgesic drugs from baseline to months 1, 3 and 6 and global assessment by the investigator at the end of the study for the three criteria: pain reduction, improved mobility and consumption of analgesics.</offsets></p><p><offsets xml_i="16995" xml_f="17033" txt_i="10274" txt_f="10312">Comparisons were made using Student’s </offsets><italic><offsets xml_i="17041" xml_f="17042" txt_i="10312" txt_f="10313">t</offsets></italic><offsets xml_i="17051" xml_f="17090" txt_i="10313" txt_f="10352"> test for quantitative criteria and Chi</offsets><sup><offsets xml_i="17095" xml_f="17096" txt_i="10352" txt_f="10353">2</offsets></sup><offsets xml_i="17102" xml_f="17255" txt_i="10353" txt_f="10506"> test for non-ordinal qualitative variables (or Fisher’s exact test) and Wilcoxon’s test for ordinal data. The threshold for significance was set at 5 %.</offsets></p><p><offsets xml_i="17262" xml_f="17338" txt_i="10507" txt_f="10583">The analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC).</offsets></p></sec></sec><sec id="Sec7" sec-type="results"><title><offsets xml_i="17395" xml_f="17402" txt_i="10586" txt_f="10593">Results</offsets></title><sec id="Sec8"><title><offsets xml_i="17432" xml_f="17455" txt_i="10594" txt_f="10617">Patient characteristics</offsets></title><p><offsets xml_i="17466" xml_f="17589" txt_i="10618" txt_f="10735">Among 132 screened patients, 112 were analyzed (20 patients were &lt;40 years of age and/or had a WOMAC subscore A &lt;25).</offsets></p><p><offsets xml_i="17596" xml_f="17665" txt_i="10736" txt_f="10805">The characteristics of patients at inclusion are summarized in Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="17699" xml_f="17700" txt_i="10805" txt_f="10806">1</offsets></xref><offsets xml_i="17707" xml_f="17871" txt_i="10806" txt_f="10970">. Two out of three patients were women and the mean age was 65.4 years (range from 44 to 88 years). Two-thirds of patients had a body mass index (BMI) above 25 kg/m</offsets><sup><offsets xml_i="17876" xml_f="17877" txt_i="10970" txt_f="10971">2</offsets></sup><offsets xml_i="17883" xml_f="18230" txt_i="10971" txt_f="11318">. The most frequent locations of knee osteoarthritis were the medial compartment (34.8 %; 39/112), tricompartmental (32.2 %; 35/112), and patello-femoral/medial femoro-tibial (10.7 %; 12/112). Radiological evaluation of osteoarthritis showed a Kellgren–Lawrence stage 2 in 64 (57, 1 %) cases, and a Kellgren–Lawrence stage 3 in 48 (42, 9 %) cases.</offsets><table-wrap id="Tab1"><label><offsets xml_i="18259" xml_f="18266" txt_i="11318" txt_f="11325">Table 1</offsets></label><caption><p><offsets xml_i="18286" xml_f="18326" txt_i="11325" txt_f="11365">Characteristics of patients at inclusion</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><offsets xml_i="18405" xml_f="18419" txt_i="11366" txt_f="11380">Characteristic</offsets></th><th align="left"><offsets xml_i="18441" xml_f="18442" txt_i="11380" txt_f="11381">
</offsets><italic><offsets xml_i="18450" xml_f="18451" txt_i="11381" txt_f="11382">N</offsets></italic><offsets xml_i="18460" xml_f="18466" txt_i="11382" txt_f="11388"> = 112</offsets></th></tr></thead><tbody><tr><td align="left" colspan="2"><offsets xml_i="18524" xml_f="18534" txt_i="11388" txt_f="11398">Age, years</offsets></td></tr><tr><td align="left"><offsets xml_i="18565" xml_f="18575" txt_i="11399" txt_f="11409"> Mean (SD)</offsets></td><td align="left"><offsets xml_i="18597" xml_f="18608" txt_i="11410" txt_f="11421">65.4 (10.6)</offsets></td></tr><tr><td align="left"><offsets xml_i="18639" xml_f="18654" txt_i="11422" txt_f="11437"> Median (range)</offsets></td><td align="left"><offsets xml_i="18676" xml_f="18686" txt_i="11438" txt_f="11448">66 (44–88)</offsets></td></tr><tr><td align="left"><offsets xml_i="18717" xml_f="18732" txt_i="11449" txt_f="11464">Female gender, </offsets><italic><offsets xml_i="18740" xml_f="18741" txt_i="11464" txt_f="11465">n</offsets></italic><offsets xml_i="18750" xml_f="18754" txt_i="11465" txt_f="11469"> (%)</offsets></td><td align="left"><offsets xml_i="18776" xml_f="18785" txt_i="11470" txt_f="11479">74 (66.1)</offsets></td></tr><tr><td align="left" colspan="2"><offsets xml_i="18828" xml_f="18843" txt_i="11480" txt_f="11495">Body mass index</offsets><sup><offsets xml_i="18848" xml_f="18849" txt_i="11495" txt_f="11496">a</offsets></sup><offsets xml_i="18855" xml_f="18861" txt_i="11496" txt_f="11502"> (kg/m</offsets><sup><offsets xml_i="18866" xml_f="18867" txt_i="11502" txt_f="11503">2</offsets></sup><offsets xml_i="18873" xml_f="18874" txt_i="11503" txt_f="11504">)</offsets></td></tr><tr><td align="left"><offsets xml_i="18905" xml_f="18915" txt_i="11505" txt_f="11515"> Mean (SD)</offsets></td><td align="left"><offsets xml_i="18937" xml_f="18947" txt_i="11516" txt_f="11526">26.4 (4.1)</offsets></td></tr><tr><td align="left"><offsets xml_i="18978" xml_f="18987" txt_i="11527" txt_f="11533"> &lt;18.5</offsets></td><td align="left"><offsets xml_i="19009" xml_f="19016" txt_i="11534" txt_f="11541">3 (2.8)</offsets></td></tr><tr><td align="left"><offsets xml_i="19047" xml_f="19057" txt_i="11542" txt_f="11552"> (18.5–25)</offsets></td><td align="left"><offsets xml_i="19079" xml_f="19088" txt_i="11553" txt_f="11562">32 (29.4)</offsets></td></tr><tr><td align="left"><offsets xml_i="19119" xml_f="19127" txt_i="11563" txt_f="11571"> (25–30)</offsets></td><td align="left"><offsets xml_i="19149" xml_f="19158" txt_i="11572" txt_f="11581">57 (52.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="19189" xml_f="19193" txt_i="11582" txt_f="11586"> ≥30</offsets></td><td align="left"><offsets xml_i="19215" xml_f="19224" txt_i="11587" txt_f="11596">17 (15.6)</offsets></td></tr><tr><td align="left" colspan="2"><offsets xml_i="19267" xml_f="19279" txt_i="11597" txt_f="11609">Study knee, </offsets><italic><offsets xml_i="19287" xml_f="19288" txt_i="11609" txt_f="11610">n</offsets></italic><offsets xml_i="19297" xml_f="19301" txt_i="11610" txt_f="11614"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="19332" xml_f="19338" txt_i="11615" txt_f="11621"> Right</offsets></td><td align="left"><offsets xml_i="19360" xml_f="19371" txt_i="11622" txt_f="11633">67 (59.8 %)</offsets></td></tr><tr><td align="left"><offsets xml_i="19402" xml_f="19407" txt_i="11634" txt_f="11639"> Left</offsets></td><td align="left"><offsets xml_i="19429" xml_f="19439" txt_i="11640" txt_f="11650">44 (3.3 %)</offsets></td></tr><tr><td align="left"><offsets xml_i="19470" xml_f="19485" txt_i="11651" txt_f="11666"> Right and left</offsets></td><td align="left"><offsets xml_i="19507" xml_f="19516" txt_i="11667" txt_f="11676">1 (0.9 %)</offsets></td></tr><tr><td align="left"><offsets xml_i="19547" xml_f="19578" txt_i="11677" txt_f="11708">Duration of knee osteoarthritis</offsets><sup><offsets xml_i="19583" xml_f="19584" txt_i="11708" txt_f="11709">b</offsets></sup><offsets xml_i="19590" xml_f="19608" txt_i="11709" txt_f="11727">, years, mean (SD)</offsets></td><td align="left"><offsets xml_i="19630" xml_f="19639" txt_i="11728" txt_f="11737">3.0 (3.5)</offsets></td></tr><tr><td align="left" colspan="2"><offsets xml_i="19682" xml_f="19702" txt_i="11738" txt_f="11758">Radiological stage, </offsets><italic><offsets xml_i="19710" xml_f="19711" txt_i="11758" txt_f="11759">n</offsets></italic><offsets xml_i="19720" xml_f="19724" txt_i="11759" txt_f="11763"> (%)</offsets></td></tr><tr><td align="left"><offsets xml_i="19755" xml_f="19764" txt_i="11764" txt_f="11773"> Grade II</offsets></td><td align="left"><offsets xml_i="19786" xml_f="19797" txt_i="11774" txt_f="11785">64 (57.1 %)</offsets></td></tr><tr><td align="left"><offsets xml_i="19828" xml_f="19838" txt_i="11786" txt_f="11796"> Grade III</offsets></td><td align="left"><offsets xml_i="19860" xml_f="19871" txt_i="11797" txt_f="11808">48 (42.9 %)</offsets></td></tr><tr><td align="left"><offsets xml_i="19902" xml_f="19920" txt_i="11809" txt_f="11827">Prior knee surgery</offsets><sup><offsets xml_i="19925" xml_f="19926" txt_i="11827" txt_f="11828">b</offsets></sup><offsets xml_i="19932" xml_f="19933" txt_i="11828" txt_f="11829">
</offsets><italic><offsets xml_i="19941" xml_f="19942" txt_i="11829" txt_f="11830">n</offsets></italic><offsets xml_i="19951" xml_f="19955" txt_i="11830" txt_f="11834"> (%)</offsets></td><td align="left"><offsets xml_i="19977" xml_f="19988" txt_i="11835" txt_f="11846">29 (27.9 %)</offsets></td></tr><tr><td align="left"><offsets xml_i="20019" xml_f="20061" txt_i="11847" txt_f="11889">Prior physical medicine and rehabilitation</offsets><sup><offsets xml_i="20066" xml_f="20067" txt_i="11889" txt_f="11890">c</offsets></sup><offsets xml_i="20073" xml_f="20074" txt_i="11890" txt_f="11891">
</offsets></td><td align="left"><offsets xml_i="20096" xml_f="20107" txt_i="11892" txt_f="11903">48 (43.6 %)</offsets></td></tr><tr><td align="left"><offsets xml_i="20138" xml_f="20181" txt_i="11904" txt_f="11947">At least one analgesic drug within 3 months</offsets></td><td align="left"><offsets xml_i="20203" xml_f="20214" txt_i="11948" txt_f="11959">87 (77.7 %)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="20260" xml_f="20261" txt_i="11960" txt_f="11961">
</offsets><sup><offsets xml_i="20266" xml_f="20267" txt_i="11961" txt_f="11962">a</offsets></sup><offsets xml_i="20273" xml_f="20304" txt_i="11962" txt_f="11993">Missing data for three patients</offsets></p><p><offsets xml_i="20311" xml_f="20312" txt_i="11994" txt_f="11995">
</offsets><sup><offsets xml_i="20317" xml_f="20318" txt_i="11995" txt_f="11996">b</offsets></sup><offsets xml_i="20324" xml_f="20355" txt_i="11996" txt_f="12027">Missing data for eight patients</offsets></p><p><offsets xml_i="20362" xml_f="20363" txt_i="12028" txt_f="12029">
</offsets><sup><offsets xml_i="20368" xml_f="20369" txt_i="12029" txt_f="12030">c</offsets></sup><offsets xml_i="20375" xml_f="20404" txt_i="12030" txt_f="12059">Missing data for two patients</offsets></p></table-wrap-foot></table-wrap></p><p><offsets xml_i="20446" xml_f="20666" txt_i="12061" txt_f="12281">The mean duration of knee osteoarthritis was 3 years; 27.9 % (29/104) of patients underwent knee surgery (the main operation was meniscectomy; 35.7 %, 10/28). The median time between operation and inclusion was 7 years (</offsets><italic><offsets xml_i="20674" xml_f="20675" txt_i="12281" txt_f="12282">n</offsets></italic><offsets xml_i="20684" xml_f="20803" txt_i="12282" txt_f="12401"> = 28). Just under half of patients had benefited from physical treatment and rehabilitation medicine (43.6 %; 48/110).</offsets></p><p><offsets xml_i="20810" xml_f="21297" txt_i="12402" txt_f="12889">About four out of five patients (77.7 %; 87/112) were taking at least one analgesic treatment during the 3 months prior to the intra-articular injections: NSAIDs for 74.1 % (83/112) of patients and an analgesic other than NSAIDs for 34.9 % (38/109) of patients. There was a moderate relief due to the analgesic treatment: on a VAS from 0 (no relief) to 100 (maximal relief), the mean relief due to the analgesic treatment was 50.8 and 53.9 according to the investigator and the patient (</offsets><italic><offsets xml_i="21305" xml_f="21306" txt_i="12889" txt_f="12890">n</offsets></italic><offsets xml_i="21315" xml_f="21336" txt_i="12890" txt_f="12911"> = 87), respectively.</offsets></p></sec><sec id="Sec9"><title><offsets xml_i="21368" xml_f="21401" txt_i="12913" txt_f="12946">Severity of pain—WOMAC subscore A</offsets></title><p><offsets xml_i="21412" xml_f="21584" txt_i="12947" txt_f="13119">On inclusion, the mean WOMAC subscore A was 52.1 (range 26–86). At 6 months, the mean WOMAC subscore A was 20.5 (range 0–80). Thus, the decrease of the subscore was −31.4 (</offsets><italic><offsets xml_i="21592" xml_f="21593" txt_i="13119" txt_f="13120">P</offsets></italic><offsets xml_i="21602" xml_f="21643" txt_i="13120" txt_f="13158"> &lt; 0.0001; Wilcoxon signed rank test).</offsets></p><p><offsets xml_i="21650" xml_f="21724" txt_i="13159" txt_f="13233">The change in the WOMAC subscore A during the study is summarized in Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="21756" xml_f="21757" txt_i="13233" txt_f="13234">1</offsets></xref><offsets xml_i="21764" xml_f="21922" txt_i="13234" txt_f="13392">, and the changes in the five items of WOMAC subscore A (A1, walking; A2, using stairs; A3, in bed; A4, sitting or lying; A5, standing) are detailed in Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="21956" xml_f="21957" txt_i="13392" txt_f="13393">2</offsets></xref><offsets xml_i="21964" xml_f="22246" txt_i="13393" txt_f="13675">. One month after the last injection, the mean score decreased to 25.7 and pain continued to decrease with a mean score of 20.4 at 3 months. This decrease in the WOMAC subscore A at 1 month and 3 months was statistically significant compared to baseline (Wilcoxon signed rank test, </offsets><italic><offsets xml_i="22254" xml_f="22255" txt_i="13675" txt_f="13676">P</offsets></italic><offsets xml_i="22264" xml_f="22278" txt_i="13676" txt_f="13687"> &lt; 0.0001).</offsets><fig id="Fig1"><label><offsets xml_i="22300" xml_f="22306" txt_i="13687" txt_f="13693">Fig. 1</offsets></label><caption><p><offsets xml_i="22326" xml_f="22446" txt_i="13693" txt_f="13813">Pain severity (WOMAC subscore A) after three injections of sodium hyaluronate-chondroitin sulfate in knee osteoarthritis</offsets></p></caption><graphic xlink:href="10195_2015_388_Fig1_HTML" id="MO1"></graphic></fig><table-wrap id="Tab2"><label><offsets xml_i="22561" xml_f="22568" txt_i="13814" txt_f="13821">Table 2</offsets></label><caption><p><offsets xml_i="22588" xml_f="22795" txt_i="13821" txt_f="14028">Pain severity (WOMAC subscore A) after three intra-articular injections of sodium hyaluronate-chondroitin sulfate. Results are given as mean (SD). For each item, pain is graded from 0 (none) to 100 (extreme)</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><offsets xml_i="22874" xml_f="22887" txt_i="14029" txt_f="14042">Time (months)</offsets></th><th align="left"><offsets xml_i="22909" xml_f="22910" txt_i="14042" txt_f="14043">0</offsets></th><th align="left"><offsets xml_i="22932" xml_f="22933" txt_i="14043" txt_f="14044">1</offsets></th><th align="left"><offsets xml_i="22955" xml_f="22956" txt_i="14044" txt_f="14045">3</offsets></th><th align="left"><offsets xml_i="22978" xml_f="22979" txt_i="14045" txt_f="14046">6</offsets></th></tr><tr><th align="left"><offsets xml_i="23010" xml_f="23011" txt_i="14046" txt_f="14047">
</offsets><italic><offsets xml_i="23019" xml_f="23020" txt_i="14047" txt_f="14048">N</offsets></italic><offsets xml_i="23029" xml_f="23030" txt_i="14048" txt_f="14049">
</offsets></th><th align="left"><offsets xml_i="23052" xml_f="23055" txt_i="14049" txt_f="14052">112</offsets></th><th align="left"><offsets xml_i="23077" xml_f="23080" txt_i="14052" txt_f="14055">111</offsets></th><th align="left"><offsets xml_i="23102" xml_f="23105" txt_i="14055" txt_f="14058">111</offsets></th><th align="left"><offsets xml_i="23127" xml_f="23130" txt_i="14058" txt_f="14061">109</offsets></th></tr></thead><tbody><tr><td align="left" colspan="5"><offsets xml_i="23188" xml_f="23204" txt_i="14061" txt_f="14077">Items of WOMAC A</offsets></td></tr><tr><td align="left"><offsets xml_i="23235" xml_f="23248" txt_i="14078" txt_f="14091"> A1 (walking)</offsets></td><td align="left"><offsets xml_i="23270" xml_f="23281" txt_i="14092" txt_f="14103">46.0 (22.2)</offsets></td><td align="left"><offsets xml_i="23303" xml_f="23314" txt_i="14104" txt_f="14115">23.3 (19.8)</offsets></td><td align="left"><offsets xml_i="23336" xml_f="23347" txt_i="14116" txt_f="14127">17.7 (18.3)</offsets></td><td align="left"><offsets xml_i="23369" xml_f="23380" txt_i="14128" txt_f="14139">16.7 (20.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="23411" xml_f="23429" txt_i="14140" txt_f="14158"> A2 (using stairs)</offsets></td><td align="left"><offsets xml_i="23451" xml_f="23462" txt_i="14159" txt_f="14170">72.1 (17.3)</offsets></td><td align="left"><offsets xml_i="23484" xml_f="23495" txt_i="14171" txt_f="14182">37.0 (22.9)</offsets></td><td align="left"><offsets xml_i="23517" xml_f="23528" txt_i="14183" txt_f="14194">31.0 (22.8)</offsets></td><td align="left"><offsets xml_i="23550" xml_f="23561" txt_i="14195" txt_f="14206">31.0 (26.7)</offsets></td></tr><tr><td align="left"><offsets xml_i="23592" xml_f="23604" txt_i="14207" txt_f="14219"> A3 (in bed)</offsets></td><td align="left"><offsets xml_i="23626" xml_f="23637" txt_i="14220" txt_f="14231">34.9 (25.2)</offsets></td><td align="left"><offsets xml_i="23659" xml_f="23670" txt_i="14232" txt_f="14243">15.5 (19.0)</offsets></td><td align="left"><offsets xml_i="23692" xml_f="23703" txt_i="14244" txt_f="14255">10.9 (17.7)</offsets></td><td align="left"><offsets xml_i="23725" xml_f="23736" txt_i="14256" txt_f="14267">10.6 (18.0)</offsets></td></tr><tr><td align="left"><offsets xml_i="23767" xml_f="23789" txt_i="14268" txt_f="14290"> A4 (sitting or lying)</offsets></td><td align="left"><offsets xml_i="23811" xml_f="23822" txt_i="14291" txt_f="14302">60.6 (21.4)</offsets></td><td align="left"><offsets xml_i="23844" xml_f="23855" txt_i="14303" txt_f="14314">30.1 (21.7)</offsets></td><td align="left"><offsets xml_i="23877" xml_f="23888" txt_i="14315" txt_f="14326">24.6 (19.4)</offsets></td><td align="left"><offsets xml_i="23910" xml_f="23921" txt_i="14327" txt_f="14338">25.4 (23.8)</offsets></td></tr><tr><td align="left"><offsets xml_i="23952" xml_f="23966" txt_i="14339" txt_f="14353"> A5 (standing)</offsets></td><td align="left"><offsets xml_i="23988" xml_f="23999" txt_i="14354" txt_f="14365">46.8 (23.5)</offsets></td><td align="left"><offsets xml_i="24021" xml_f="24032" txt_i="14366" txt_f="14377">22.4 (22.5)</offsets></td><td align="left"><offsets xml_i="24054" xml_f="24065" txt_i="14378" txt_f="14389">17.7 (18.8)</offsets></td><td align="left"><offsets xml_i="24087" xml_f="24098" txt_i="14390" txt_f="14401">18.8 (22.2)</offsets></td></tr><tr><td align="left"><offsets xml_i="24129" xml_f="24136" txt_i="14402" txt_f="14409">WOMAC A</offsets></td><td align="left"><offsets xml_i="24158" xml_f="24169" txt_i="14410" txt_f="14421">52.1 (15.2)</offsets><sup><offsets xml_i="24174" xml_f="24175" txt_i="14421" txt_f="14422">a</offsets></sup><offsets xml_i="24181" xml_f="24182" txt_i="14422" txt_f="14423">
</offsets></td><td align="left"><offsets xml_i="24204" xml_f="24215" txt_i="14424" txt_f="14435">25.7 (17.4)</offsets><sup><offsets xml_i="24220" xml_f="24221" txt_i="14435" txt_f="14436">a</offsets></sup><offsets xml_i="24227" xml_f="24228" txt_i="14436" txt_f="14437">
</offsets></td><td align="left"><offsets xml_i="24250" xml_f="24261" txt_i="14438" txt_f="14449">20.4 (16.3)</offsets><sup><offsets xml_i="24266" xml_f="24267" txt_i="14449" txt_f="14450">a</offsets></sup><offsets xml_i="24273" xml_f="24274" txt_i="14450" txt_f="14451">
</offsets></td><td align="left"><offsets xml_i="24296" xml_f="24307" txt_i="14452" txt_f="14463">20.5 (19.7)</offsets><sup><offsets xml_i="24312" xml_f="24313" txt_i="14463" txt_f="14464">a</offsets></sup><offsets xml_i="24319" xml_f="24320" txt_i="14464" txt_f="14465">
</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="24366" xml_f="24367" txt_i="14466" txt_f="14467">
</offsets><sup><offsets xml_i="24372" xml_f="24373" txt_i="14467" txt_f="14468">a</offsets></sup><offsets xml_i="24379" xml_f="24406" txt_i="14468" txt_f="14495">No treatment baseline score</offsets></p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title><offsets xml_i="24474" xml_f="24485" txt_i="14498" txt_f="14509">Pain relief</offsets></title><p><offsets xml_i="24496" xml_f="24865" txt_i="14510" txt_f="14879">One month after the last intra-articular injection, the mean pain relief was assessed at 35.9 (25.6) on VAS by patients (0, maximal pain relief; 100, no relief). Pain relief continued to decrease at 3 and 6 months: 28.1 (23.1) and 26.1 (25.4), respectively. Compared to the values at 1 month, the values of pain relief at 3 and 6 months were statistically significant (</offsets><italic><offsets xml_i="24873" xml_f="24874" txt_i="14879" txt_f="14880">P</offsets></italic><offsets xml_i="24883" xml_f="24900" txt_i="14880" txt_f="14894"> &lt; 0.0001 and </offsets><italic><offsets xml_i="24908" xml_f="24909" txt_i="14894" txt_f="14895">P</offsets></italic><offsets xml_i="24918" xml_f="24943" txt_i="14895" txt_f="14920"> = 0.0048, respectively).</offsets></p></sec><sec id="Sec11"><title><offsets xml_i="24976" xml_f="25006" txt_i="14922" txt_f="14952">Consumption of analgesic drugs</offsets></title><p><offsets xml_i="25017" xml_f="25480" txt_i="14953" txt_f="15416">One month after the last intra-articular injection, the patients assessed on a VAS their mean consumption of analgesic drugs from 0 (no consumption of analgesics) to 100 (maximal consumption of analgesics). The mean (SD) consumption decreased with time: 28.6 (24.4) at 1 month, 19.9 (21.7) at 3 months and 17.1 (22.3) at 6 months. Compared to the values at 1 month, the scores of the consumption of analgesic drugs at 3 and 6 months were significantly decreased (</offsets><italic><offsets xml_i="25488" xml_f="25489" txt_i="15416" txt_f="15417">P</offsets></italic><offsets xml_i="25498" xml_f="25527" txt_i="15417" txt_f="15443"> &lt; 0.0001 for both times).</offsets></p></sec><sec id="Sec12"><title><offsets xml_i="25560" xml_f="25594" txt_i="15445" txt_f="15479">Global assessment by investigators</offsets></title><p><offsets xml_i="25605" xml_f="25846" txt_i="15480" txt_f="15721">The investigators were satisfied or very satisfied as regards the therapeutic effectiveness of sodium hyaluronate-chondroitin sulfate in reducing pain (77 %), improving mobility (78 %) and reducing the consumption of analgesics (74 %) (Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="25878" xml_f="25879" txt_i="15721" txt_f="15722">2</offsets></xref><offsets xml_i="25886" xml_f="25888" txt_i="15722" txt_f="15724">).</offsets><fig id="Fig2"><label><offsets xml_i="25910" xml_f="25916" txt_i="15724" txt_f="15730">Fig. 2</offsets></label><caption><p><offsets xml_i="25936" xml_f="26071" txt_i="15730" txt_f="15865">Overall assessment of efficacy of three injections of sodium hyaluronate-chondroitin sulfate in knee osteoarthritis by the investigator</offsets></p></caption><graphic xlink:href="10195_2015_388_Fig2_HTML" id="MO2"></graphic></fig></p><p><offsets xml_i="26164" xml_f="26352" txt_i="15867" txt_f="16055">Overall, about 80 % of investigators stated that the results of the intra-articular injections of sodium hyaluronate-chondroitin sulfate combination were satisfactory or very satisfactory.</offsets></p></sec><sec id="Sec13"><title><offsets xml_i="26385" xml_f="26398" txt_i="16057" txt_f="16070">Complications</offsets></title><p><offsets xml_i="26409" xml_f="26560" txt_i="16071" txt_f="16222">One adverse effect was reported by one patient. This adverse event was knee tumefaction, which lasted 3 days after the first intra-articular injection.</offsets></p></sec></sec><sec id="Sec14" sec-type="discussion"><title><offsets xml_i="26621" xml_f="26631" txt_i="16225" txt_f="16235">Discussion</offsets></title><p><offsets xml_i="26642" xml_f="26811" txt_i="16236" txt_f="16405">Viscosupplementation with hyaluronic acid alone has demonstrated moderate but significant effectiveness vs placebo in terms of pain and function in knee osteoarthritis [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="26844" xml_f="26846" txt_i="16405" txt_f="16407">11</offsets></xref><offsets xml_i="26853" xml_f="26965" txt_i="16407" txt_f="16519">]. Our study is the first, to our knowledge, to assess the effectiveness and safety of injections of Arthrum HCS</offsets><sup><offsets xml_i="26970" xml_f="26971" txt_i="16519" txt_f="16520">®</offsets></sup><offsets xml_i="26977" xml_f="27628" txt_i="16520" txt_f="17171"> in a relatively large population of patients with knee osteoarthritis. We observed that the severity of pain assessed with the WOMAC subscore A decreased significantly from 52.1 to 20.5 at 6 months. The relief was already significant 1 month after the last injection. These results were confirmed by the assessment of pain relief and the decrease in the consumption of analgesics with VAS. Approximately three out of four investigators were satisfied/very satisfied as regards to the therapeutic effectiveness of the injections of sodium hyaluronate-chondroitin sulfate in reducing pain, improving mobility and reducing the consumption of analgesics.</offsets></p><p><offsets xml_i="27635" xml_f="27668" txt_i="17172" txt_f="17205">The pilot study of Maheu et al. [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="27701" xml_f="27703" txt_i="17205" txt_f="17207">17</offsets></xref><offsets xml_i="27710" xml_f="28148" txt_i="17207" txt_f="17645">] in 41 patients with femoro-tibial knee osteoarthritis also reported an improvement 3 months after three 2-mL injections of hyaluronic acid (12 mg/mL) plus chondroitin sulfate (30 mg/mL). The mean VAS score decreased from 61 at baseline to 29 after 3 months (60 % of patients reported an improvement above 50 %). Although the dosages of the compounds were slightly different, these results are consistent with those of the present study.</offsets></p><p><offsets xml_i="28155" xml_f="28498" txt_i="17646" txt_f="17989">The very low proportion of patients with adverse events confirms the safety of viscosupplementation in knee osteoarthritis. The harmlessness of viscosupplementation in knee osteoarthritis has been confirmed in a recent systematic review and meta-analysis of randomized saline-controlled trials for US-approved intra-articular hyaluronic acid [</offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="28531" xml_f="28533" txt_i="17989" txt_f="17991">24</offsets></xref><offsets xml_i="28540" xml_f="28662" txt_i="17991" txt_f="18113">]. There were no statistically significant differences between hyaluronic acid and saline controls for any safety outcome.</offsets></p><p><offsets xml_i="28669" xml_f="28793" txt_i="18114" txt_f="18238">It is now debated that surgical procedures in knee osteoarthritis should be avoided as far as possible or at least delayed [</offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="28826" xml_f="28828" txt_i="18238" txt_f="18240">25</offsets></xref><offsets xml_i="28835" xml_f="28837" txt_i="18240" txt_f="18242">, </offsets><xref ref-type="bibr" rid="CR26"><offsets xml_i="28870" xml_f="28872" txt_i="18242" txt_f="18244">26</offsets></xref><offsets xml_i="28879" xml_f="29268" txt_i="18244" txt_f="18633">]. The restoration of the viscoelasticity of the synovial fluid in order to protect cartilage, if possible during the early states of the disease, is an attractive therapeutic option. Moreover, a medico-economic evaluation showed that, together with clinical benefits, costs of knee osteoarthritis decreased after hyaluronic acid injections due to the decreased need for other treatments [</offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="29301" xml_f="29303" txt_i="18633" txt_f="18635">23</offsets></xref><offsets xml_i="29310" xml_f="29537" txt_i="18635" txt_f="18862">]. However no therapies have been shown to alter the natural history of osteoarthritis. In the absence of disease modifying osteoarthritis drugs, treatment of osteoarthritis is focused on controlling symptoms, especially pain [</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="29570" xml_f="29572" txt_i="18862" txt_f="18864">10</offsets></xref><offsets xml_i="29579" xml_f="29581" txt_i="18864" txt_f="18866">, </offsets><xref ref-type="bibr" rid="CR27"><offsets xml_i="29614" xml_f="29616" txt_i="18866" txt_f="18868">27</offsets></xref><offsets xml_i="29623" xml_f="29625" txt_i="18868" txt_f="18870">, </offsets><xref ref-type="bibr" rid="CR28"><offsets xml_i="29658" xml_f="29660" txt_i="18870" txt_f="18872">28</offsets></xref><offsets xml_i="29667" xml_f="29878" txt_i="18872" txt_f="19083">]. Until prospective studies on the efficacy of hyaluronic acid on knee arthroplasty delay are completed, intra-articular treatment must be considered an additional non-operative strategy for relief of symptoms.</offsets></p><p><offsets xml_i="29885" xml_f="30141" txt_i="19084" txt_f="19340">There are some limitations of the study. First, there was no control group. Indeed, there is a debate on the effectiveness of viscosupplementation in osteoarthritis, but some meta-analyses found an advantage of viscosupplementation over sham intervention [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="30174" xml_f="30176" txt_i="19340" txt_f="19342">14</offsets></xref><offsets xml_i="30183" xml_f="30185" txt_i="19342" txt_f="19344">, </offsets><xref ref-type="bibr" rid="CR24"><offsets xml_i="30218" xml_f="30220" txt_i="19344" txt_f="19346">24</offsets></xref><offsets xml_i="30227" xml_f="30229" txt_i="19346" txt_f="19348">, </offsets><xref ref-type="bibr" rid="CR25"><offsets xml_i="30262" xml_f="30264" txt_i="19348" txt_f="19350">25</offsets></xref><offsets xml_i="30271" xml_f="30591" txt_i="19350" txt_f="19670">]. Therefore, it was difficult to justify a sham control in one group. Nevertheless, the kinetics of the effect observed in the present study conform to the conclusions of a meta-analysis on viscosupplementation that showed that effectiveness became significant at 4 weeks, peaked at 8 weeks and persisted for 6 months [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="30624" xml_f="30626" txt_i="19670" txt_f="19672">14</offsets></xref><offsets xml_i="30633" xml_f="30976" txt_i="19672" txt_f="20015">]. Another limitation was the absence of demonstration of the benefit of the addition of chondroitin sulfate to hyaluronic acid. With a comparable total number of patients, the statistical power of the trial would decrease with an additional treatment group (hyaluronic acid alone). This issue should certainly be addressed in further studies.</offsets></p><p><offsets xml_i="30983" xml_f="30994" txt_i="20016" txt_f="20027">Arthrum HCS</offsets><sup><offsets xml_i="30999" xml_f="31000" txt_i="20027" txt_f="20028">®</offsets></sup><offsets xml_i="31006" xml_f="31290" txt_i="20028" txt_f="20312"> is a new intra-articular treatment combining in the same injection two compounds that are deficient in osteoarthritis. Chondroitin sulfate is an essential component of cartilage and is present also in synovial fluid. Our results suggest that intra-articular injections of Arthrum HCS</offsets><sup></sup><offsets xml_i="31301" xml_f="31497" txt_i="20312" txt_f="20508"> (sodium hyaluronate plus chondroitin sulfate) in patients with knee osteoarthritis allows a safe and effective control of pain. These results should be confirmed in a randomized controlled study.</offsets></p></sec></body><back><notes notes-type="conflict-interest"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflict of interest</title><p>All authors received a consultancy fee reimbursement from LCA Pharmaceutical, Chartres, France, to contribute to completing this study. This research received no specific grant from any funding agency in the public, or not-for-profit sectors.</p></sec><sec id="FPar2"><title>Ethical standards</title><p>All patients gave informed consent prior being included into the study. All procedures involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments. The study was approved by the Research Ethics Committee.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJ</given-names></name><name><surname>Vos</surname><given-names>T</given-names></name><name><surname>Lozano</surname><given-names>R</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Flaxman</surname><given-names>AD</given-names></name><name><surname>Michaud</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>2197</fpage><lpage>2223</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61689-4</pub-id><pub-id pub-id-type="pmid">23245608</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guccione</surname><given-names>AA</given-names></name><name><surname>Felson</surname><given-names>DT</given-names></name><name><surname>Anderson</surname><given-names>JJ</given-names></name><name><surname>Anthony</surname><given-names>JM</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><etal></etal></person-group><article-title>The effects of specific medical conditions on the functional limitations of elders in the Framingham study</article-title><source>Am J Public Health</source><year>1994</year><volume>84</volume><fpage>351</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.2105/AJPH.84.3.351</pub-id><pub-id pub-id-type="pmid">8129049</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Hawker</surname><given-names>GA</given-names></name><name><surname>Laporte</surname><given-names>A</given-names></name><name><surname>Croxford</surname><given-names>R</given-names></name><name><surname>Coyte</surname><given-names>PC</given-names></name></person-group><article-title>The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition</article-title><source>Rheumatology</source><year>2005</year><volume>44</volume><fpage>1531</fpage><lpage>1537</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kei049</pub-id><pub-id pub-id-type="pmid">16091394</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Pen</surname><given-names>C</given-names></name><name><surname>Reygrobellet</surname><given-names>C</given-names></name><name><surname>Gerentes</surname><given-names>I</given-names></name></person-group><article-title>Financial cost of osteoarthritis in France. The “COART” France study</article-title><source>Joint Bone Spine</source><year>2005</year><volume>72</volume><fpage>567</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1016/j.jbspin.2005.01.011</pub-id><pub-id pub-id-type="pmid">16226481</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>DJ</given-names></name></person-group><article-title>Osteoarthritis</article-title><source>Best Pract Res Clin Rheumatol</source><year>2011</year><volume>25</volume><fpage>801</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1016/j.berh.2011.11.008</pub-id><pub-id pub-id-type="pmid">22265262</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>DJ</given-names></name></person-group><article-title>Viscosupplementation for osteoarthritis of the knee</article-title><source>N Engl J Med</source><year>2015</year><volume>372</volume><fpage>1040</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1056/NEJMct1215534</pub-id><pub-id pub-id-type="pmid">25760356</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennell</surname><given-names>KL</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Hinman</surname><given-names>RS</given-names></name></person-group><article-title>Management of osteoarthritis of the knee</article-title><source>BMJ</source><year>2012</year><volume>345</volume><fpage>e4934</fpage><pub-id pub-id-type="doi">10.1136/bmj.e4934</pub-id><pub-id pub-id-type="pmid">22846469</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>Altman</surname><given-names>RD</given-names></name><name><surname>April</surname><given-names>KT</given-names></name><name><surname>Benkhalti</surname><given-names>M</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>McGowan</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee</article-title><source>Arthritis Care Res (Hoboken)</source><year>2012</year><volume>64</volume><fpage>465</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1002/acr.21596</pub-id><pub-id pub-id-type="pmid">22563589</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Nuki</surname><given-names>G</given-names></name><name><surname>Moskowitz</surname><given-names>RW</given-names></name><name><surname>Abramson</surname><given-names>S</given-names></name><name><surname>Altman</surname><given-names>RD</given-names></name><name><surname>Arden</surname><given-names>NK</given-names></name></person-group><article-title>OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009</article-title><source>Osteoarthr Cartil</source><year>2010</year><volume>18</volume><fpage>476</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2010.01.013</pub-id><pub-id pub-id-type="pmid">20170770</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jevsevar</surname><given-names>DS</given-names></name></person-group><article-title>Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition</article-title><source>J Am Acad Orthop Surg</source><year>2013</year><volume>21</volume><fpage>571</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">23996988</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legre-Boyer</surname><given-names>V</given-names></name></person-group><article-title>Viscosupplementation: techniques, indications, results</article-title><source>Orthop Traumatol Surg Res</source><year>2015</year><volume>101</volume><fpage>S101</fpage><lpage>S108</lpage><pub-id pub-id-type="doi">10.1016/j.otsr.2014.07.027</pub-id><pub-id pub-id-type="pmid">25596987</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balazs</surname><given-names>EA</given-names></name><name><surname>Denlinger</surname><given-names>JL</given-names></name></person-group><article-title>Viscosupplementation: a new concept in the treatment of osteoarthritis</article-title><source>J Rheumatol Suppl</source><year>1993</year><volume>39</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8410881</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pederzini</surname><given-names>LA</given-names></name><name><surname>Milandri</surname><given-names>L</given-names></name><name><surname>Tosi</surname><given-names>M</given-names></name><name><surname>Prandini</surname><given-names>M</given-names></name><name><surname>Nicoletta</surname><given-names>F</given-names></name></person-group><article-title>Preliminary clinical experience with hyaluronan anti-adhesion gel in arthroscopic arthrolysis for posttraumatic elbow stiffness</article-title><source>J Orthopaed Traumatol</source><year>2013</year><volume>14</volume><issue>2</issue><fpage>109</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1007/s10195-013-0229-z</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannuru</surname><given-names>RR</given-names></name><name><surname>Natov</surname><given-names>NS</given-names></name><name><surname>Obadan</surname><given-names>IE</given-names></name><name><surname>Price</surname><given-names>LL</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><name><surname>McAlindon</surname><given-names>TE</given-names></name></person-group><article-title>Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis</article-title><source>Arthritis Rheum</source><year>2009</year><volume>261</volume><fpage>1704</fpage><lpage>1711</lpage><pub-id pub-id-type="doi">10.1002/art.24925</pub-id><pub-id pub-id-type="pmid">19950318</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CT</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>CJ</given-names></name><name><surname>Lin</surname><given-names>YT</given-names></name><name><surname>Hou</surname><given-names>SM</given-names></name></person-group><article-title>Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials</article-title><source>J Bone Joint Surg Am</source><year>2004</year><volume>86</volume><fpage>538</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">14996880</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bali</surname><given-names>JP</given-names></name><name><surname>Cousse</surname><given-names>H</given-names></name><name><surname>Neuzil</surname><given-names>E</given-names></name></person-group><article-title>Biochemical basis of the pharmacologic action of chondroitin sulfates on the osteoarticular system</article-title><source>Semin Arthritis Rheum</source><year>2001</year><volume>31</volume><issue>1</issue><fpage>58</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1053/sarh.2000.24874</pub-id><pub-id pub-id-type="pmid">11503140</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Maheu E, Zaïm M, Appelboom T, Bensaber M, Cadet C, Saurel A (2010) Evaluation of intra articular injections of hyaluronic acid and chondroitine sulfate for knee arthritis treatment: a multicentric pilot study with 3 monts follow-up. National rheumatolgy meeting 2010 (Société Française de Rhumatologie). <ext-link ext-link-type="uri" xlink:href="http://www.rhumatologie.asso.fr/data/ModuleProgramme/PageSite/2010-1/Resume/6007.asp">http://www.rhumatologie.asso.fr/data/ModuleProgramme/PageSite/2010-1/Resume/6007.asp</ext-link>. Accessed<italic> date</italic> 2015</mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Tosun HB, Gumustas S, Agir I, Uludag A, Serbest S, Pepele D (2015) Comparison of the effects of sodium hyaluronate-chondroitin sulphate and corticosteroid in the treatment of lateral epicondylitis: a prospective randomized trial. J Orthop Sci 20:837–843</mixed-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henrotin</surname><given-names>Y</given-names></name><name><surname>Hauzeur</surname><given-names>JP</given-names></name><name><surname>Bruel</surname><given-names>P</given-names></name><name><surname>Appelboom</surname><given-names>T</given-names></name></person-group><article-title>Intra-articular use of a medical device composed of hyaluronic acid and chondroitin sulfate (Structovial CS): effects on clinical, ultrasonographic and biological parameters</article-title><source>BMC Res Notes</source><year>2012</year><volume>5</volume><fpage>407</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1186/1756-0500-5-407</pub-id><pub-id pub-id-type="pmid">22862789</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlbäck</surname><given-names>S</given-names></name></person-group><article-title>Osteoarthrosis of the knee: a radiographic investigation</article-title><source>Acta Radiol Stockholm</source><year>1968</year><volume>suppl 277</volume><fpage>70</fpage><lpage>72</lpage></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConnell</surname><given-names>S</given-names></name><name><surname>Kolopack</surname><given-names>P</given-names></name><name><surname>Davis</surname><given-names>AM</given-names></name></person-group><article-title>The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): a review of its utility and measurement properties</article-title><source>Arthritis Rheum</source><year>2001</year><volume>45</volume><fpage>453</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(200110)45:5&lt;453::AID-ART365&gt;3.0.CO;2-W</pub-id><pub-id pub-id-type="pmid">11642645</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrich</surname><given-names>EW</given-names></name><name><surname>Davies</surname><given-names>GM</given-names></name><name><surname>Watson</surname><given-names>DJ</given-names></name><name><surname>Bolognese</surname><given-names>JA</given-names></name><name><surname>Seidenberg</surname><given-names>BC</given-names></name><name><surname>Bellamy</surname><given-names>N</given-names></name></person-group><article-title>Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis</article-title><source>J Rheumatol</source><year>2000</year><volume>27</volume><fpage>2635</fpage><lpage>2641</lpage><pub-id pub-id-type="pmid">11093446</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazieres</surname><given-names>B</given-names></name><name><surname>Bard</surname><given-names>H</given-names></name><name><surname>Ligier</surname><given-names>M</given-names></name><name><surname>Bru</surname><given-names>I</given-names></name><name><surname>d’Orsay</surname><given-names>GG</given-names></name><name><surname>Le Pen</surname><given-names>C</given-names></name></person-group><article-title>Medicoeconomic evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: the MESSAGE study</article-title><source>Joint Bone Spine</source><year>2007</year><volume>74</volume><fpage>453</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.jbspin.2007.01.037</pub-id><pub-id pub-id-type="pmid">17921022</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>LE</given-names></name><name><surname>Block</surname><given-names>JE</given-names></name></person-group><article-title>US-approved intra-articular hyaluronic acid injections are safe and effective in patients with knee osteoarthritis: systematic review and meta-analysis of randomized, saline-controlled trials</article-title><source>Clin Med Insights Arthritis Musculoskelet Disord</source><year>2013</year><volume>6</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">24027421</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>GH</given-names></name><name><surname>LaValley</surname><given-names>M</given-names></name><name><surname>McAlindon</surname><given-names>T</given-names></name><name><surname>Felson</surname><given-names>DT</given-names></name></person-group><article-title>Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis</article-title><source>JAMA</source><year>2003</year><volume>290</volume><fpage>3115</fpage><lpage>3121</lpage><pub-id pub-id-type="doi">10.1001/jama.290.23.3115</pub-id><pub-id pub-id-type="pmid">14679274</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbott</surname><given-names>Thomas</given-names></name><name><surname>Altman</surname><given-names>Roy D</given-names></name><name><surname>Dimeff</surname><given-names>Robert</given-names></name><name><surname>Fredericson</surname><given-names>Michael</given-names></name><name><surname>Vad</surname><given-names>Vijay</given-names></name><name><surname>Vitanzo</surname><given-names>Peter</given-names></name><etal></etal></person-group><article-title>Do hyaluronic acid injections delay total knee replacement surgery? [abstract]</article-title><source>Arthritis Rheum</source><year>2013</year><volume>65</volume><issue>Suppl 10</issue><fpage>2139</fpage></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American College of Rheumatology Subcommittee on Osteoarthritis Guidelines</collab></person-group><article-title>Recommendations for the medical management of osteoarthritis of the hip and knee</article-title><source>Arthritis Rheum</source><year>2000</year><volume>43</volume><issue>9</issue><fpage>1905</fpage><lpage>1915</lpage><pub-id pub-id-type="doi">10.1002/1529-0131(200009)43:9&lt;1905::AID-ANR1&gt;3.0.CO;2-P</pub-id><pub-id pub-id-type="pmid">11014340</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Nuki</surname><given-names>G</given-names></name><name><surname>Moskowitz</surname><given-names>RW</given-names></name><name><surname>Abramson</surname><given-names>S</given-names></name><name><surname>Altman</surname><given-names>RD</given-names></name><name><surname>Arden</surname><given-names>NK</given-names></name><etal></etal></person-group><article-title>OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009</article-title><source>Osteoarthr Cartil</source><year>2010</year><volume>18</volume><issue>4</issue><fpage>476</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2010.01.013</pub-id><pub-id pub-id-type="pmid">20170770</pub-id></element-citation></ref></ref-list></back></article>